Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.

Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for intismeran plus KEYTRUDA.

MRK remains a defensive, yield-generating diversification play, but near-term upside appears constrained by valuation and expectations.

A Barchart report shows that despite recent strong Q2 results and a 10% spike in Merck stock today, an unusually large volume of put options has traded at a much lower strike price. Is MRK stock overvalued?

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to bolster patient access to community-based oncology trials. | Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co.

New Drugs Are Driving Revenue Merck & Co. recently released its second-quarter results. The US company remains strategically on track. The focus is on diversifying the product portfolio ahead of the expiration of Keytruda’s main patents in 2028.

Shares of Merck and Amgen are posting positive gains Wednesday morning, lifting the Dow Jones Industrial Average into positive territory. Shares of Merck and Amgen have contributed to the blue-chip gauge's intraday rally,

Dell Technologies DELL, JPMorgan Chase & Co. JPM and Merck & Co. MRK all touched fresh all-time highs on Thursday — with Dell hitting $514, JPMorgan reaching $366.50 and Merck climbing to $135.68, according to Benzinga Pro data.